pfizer cedes control of diabetes drug in response to complaints from nektar therapeutics that pfizer inc didnt properly market their jointly developed diabetes therapy exubera pfizer said it will turn over its commercial interest in the inhaled insulin product to nektar in addition to a substantial payment the move comes about a month after pfizer announced it would cease marketing exubera because of poor sales as a result pfizer said yesterday that it plans to pay nektar &# million in addition to turning over commercial interests and pending regulatory filings for the product nektar a specialist in drug delivery technology developed the capability that lets insulin be administered through a large inhalation device the deal also calls for nektar to assume development of a next generation of the product which posted sales of only &# million in the second quarter exubera never gained traction in the marketplace primarily because of concerns about long term impacts it might have on the lungs 
